AstraZeneca PLC (FRA:ZEG)
Germany
· Delayed Price · Currency is EUR 128.75
-0.45 (-0.35%)
At close: Jun 11, 2025, 10:00 PM CET
AstraZeneca Revenue
AstraZeneca had revenue of $13.59B USD in the quarter ending March 31, 2025, with 7.17% growth. This brings the company's revenue in the last twelve months to $54.98B, up 15.48% year-over-year. In the year 2024, AstraZeneca had annual revenue of $54.07B with 18.03% growth.
Revenue (ttm)
$54.98B
Revenue Growth
+15.48%
P/S Ratio
3.95
Revenue / Employee
$583.05K
Employees
94,300
Market Cap
200.77B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
| Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
| Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
| Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
| Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SAP SE | 35.15B |
| Siemens Aktiengesellschaft | 77.82B |
| Deutsche Telekom AG | 120.25B |
| Allianz SE | 109.03B |
| Rheinmetall AG | 10.48B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 61.84B |
| Siemens Energy AG | 37.44B |
| Siemens Healthineers AG | 23.14B |
AstraZeneca News
- 2 days ago - I attended the world's biggest cancer conference. Doctors gave standing ovations to 2 major breakthroughs. - Business Insider
- 3 days ago - Merck wins FDA nod for RSV shot for infants, challenging Sanofi/ AstraZeneca - Seeking Alpha
- 3 days ago - What's Going On With IonQ Shares Monday? - Benzinga
- 3 days ago - FDA approves Mercks RSV shot for infants, ramping up competition with Sanofi and AstraZeneca - CNBC
- 4 days ago - DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer - Benzinga
- 4 days ago - IonQ, AstraZeneca, Nvidia and AWS show quantum-accelerated drug development workflow - Seeking Alpha
- 6 days ago - AstraZeneca: Fascinating Company With Lofty Ambitions - Just Not A Buy Yet - Seeking Alpha
- 7 days ago - AstraZeneca’s £1 Billion Cambridge Hub Fuels UK Biotech Surge - ABC Money